Print Page  |  Close Window

Investor Relations

Overview
Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. OTIPRIO® (ciprofloxacin otic suspension) is approved in the United States for use during tympanostomy tube placement surgery in pediatric patients, an sNDA has been accepted for filing by the FDA for acute otitis externa (AOE) and a successful End-of-Phase 2 review has been completed with the FDA for acute otitis media with tympanostomy tubes (AOMT). OTIVIDEX™ is a steroid in late-stage clinical development for the treatment of Ménière’s disease. OTO-311 is an NMDA receptor antagonist for the treatment of tinnitus that has completed a Phase 1 clinical safety trial. Multiple programs targeting sensorineural hearing loss including age-related hearing loss are in preclinical development. These programs involve the anatomical and functional restoration of ribbon synapses, protection of hair cells from chemotoxicity, and regeneration of hair cells.
Stock Quote
OTIC (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$5.55
Change (%) Stock is Up 0.05 (0.91%)
Volume843,737
Data as of 11/17/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock Chart
Stock chart for: OTIC.OQ.  Currently trading at $5.55 with a 52 week high of $21.15 and a 52 week low of $2.80.
Recent NewsMore >>
DateTitle 
11/08/17Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
11/08/17Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX™ in Patients with Ménière's DiseasePrinter Friendly Version
Investor Presentations
Download Documentation AVERTS-2 Topline Results
Download Documentation AVERTS-1 Topline Results
Download Documentation Meniere’s Disease KOL Breakfast
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Otonomy Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources